Marinus Pharmaceuticals Inc (MRNS)
1.475
+0.02
(+1.03%)
USD |
NASDAQ |
May 02, 10:16
Marinus Pharmaceuticals Enterprise Value: 2.885M for May 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 01, 2024 | 2.885M |
| April 30, 2024 | 0.1387M |
| April 29, 2024 | -0.4106M |
| April 26, 2024 | -0.1359M |
| April 25, 2024 | 0.688M |
| April 24, 2024 | 1.787M |
| April 23, 2024 | 1.787M |
| April 22, 2024 | 3.709M |
| April 19, 2024 | -1.509M |
| April 18, 2024 | 0.1387M |
| April 17, 2024 | 1.787M |
| April 16, 2024 | -11.40M |
| April 15, 2024 | -5.904M |
| April 12, 2024 | 335.77M |
| April 11, 2024 | 357.74M |
| April 10, 2024 | 367.08M |
| April 09, 2024 | 383.01M |
| April 08, 2024 | 373.12M |
| April 05, 2024 | 351.15M |
| April 04, 2024 | 399.49M |
| April 03, 2024 | 400.59M |
| April 02, 2024 | 409.92M |
| April 01, 2024 | 415.42M |
| March 28, 2024 | 416.66M |
| March 27, 2024 | 406.27M |
| Date | Value |
|---|---|
| March 26, 2024 | 402.99M |
| March 25, 2024 | 410.64M |
| March 22, 2024 | 404.09M |
| March 21, 2024 | 415.02M |
| March 20, 2024 | 416.66M |
| March 19, 2024 | 430.86M |
| March 18, 2024 | 415.56M |
| March 15, 2024 | 435.78M |
| March 14, 2024 | 411.74M |
| March 13, 2024 | 438.51M |
| March 12, 2024 | 429.77M |
| March 11, 2024 | 386.06M |
| March 08, 2024 | 406.27M |
| March 07, 2024 | 400.81M |
| March 06, 2024 | 416.11M |
| March 05, 2024 | 427.58M |
| March 04, 2024 | 443.98M |
| March 01, 2024 | 464.74M |
| February 29, 2024 | 441.79M |
| February 28, 2024 | 461.04M |
| February 27, 2024 | 468.69M |
| February 26, 2024 | 468.14M |
| February 23, 2024 | 456.13M |
| February 22, 2024 | 447.94M |
| February 21, 2024 | 455.04M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-11.40M
Minimum
Apr 16 2024
599.59M
Maximum
Jul 09 2021
249.72M
Average
237.06M
Median
May 31 2023
Enterprise Value Benchmarks
| Ligand Pharmaceuticals Inc | 1.095B |
| Soligenix Inc | -0.9249M |
| Actinium Pharmaceuticals Inc | 147.66M |
| Macrogenics Inc | 741.01M |
| ADMA Biologics Inc | 1.601B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -41.77M |
| Revenue (Quarterly) | 7.19M |
| Total Expenses (Quarterly) | 42.63M |
| EPS Diluted (Quarterly) | -0.74 |
| Gross Profit Margin (Quarterly) | 87.66% |
| Profit Margin (Quarterly) | -580.9% |
| Earnings Yield | -178.3% |
| Normalized Earnings Yield | -178.31 |